Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $8,221,000.00 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $411.05, for a total value of $8,221,000.00. Following the sale, the chief executive officer now owns 260,446 shares in the company, valued at $107,056,328.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

NYSE:TMO opened at $413.95 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $250.21 and a 12-month high of $420.99. The firm has a market capitalization of $163.49 billion, a P/E ratio of 44.80, a P/E/G ratio of 1.83 and a beta of 1.04. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.62 and a quick ratio of 2.02. The business has a 50 day simple moving average of $373.97 and a 200 day simple moving average of $335.37.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 22nd. The medical research company reported $3.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.22. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The business had revenue of $6.92 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the previous year, the firm posted $3.04 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 14.95 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Monday, September 14th. This represents a $0.88 dividend on an annualized basis and a yield of 0.21%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.13%.

Hedge funds have recently made changes to their positions in the business. Laurel Wealth Advisors LLC boosted its position in Thermo Fisher Scientific by 104.3% during the 1st quarter. Laurel Wealth Advisors LLC now owns 94 shares of the medical research company’s stock worth $27,000 after acquiring an additional 48 shares during the period. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in Thermo Fisher Scientific during the 1st quarter worth $28,000. Liberty One Investment Management LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $41,000. JJJ Advisors Inc. raised its stake in shares of Thermo Fisher Scientific by 36.5% in the 2nd quarter. JJJ Advisors Inc. now owns 116 shares of the medical research company’s stock worth $42,000 after buying an additional 31 shares in the last quarter. Finally, Investors Research Corp raised its stake in shares of Thermo Fisher Scientific by 100.0% in the 2nd quarter. Investors Research Corp now owns 120 shares of the medical research company’s stock worth $39,000 after buying an additional 60 shares in the last quarter. Institutional investors own 87.51% of the company’s stock.

Several equities research analysts have issued reports on the company. Cowen restated a “buy” rating and set a $380.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Stifel Nicolaus lifted their target price on Thermo Fisher Scientific from $370.00 to $460.00 and gave the stock a “buy” rating in a research report on Thursday, July 23rd. Wells Fargo & Co lifted their target price on Thermo Fisher Scientific from $300.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 21st. Needham & Company LLC lifted their target price on Thermo Fisher Scientific from $415.00 to $468.00 and gave the stock a “buy” rating in a research report on Thursday, July 23rd. Finally, SVB Leerink lifted their target price on Thermo Fisher Scientific from $365.00 to $455.00 and gave the stock an “outperform” rating in a research report on Thursday, July 23rd. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $420.50.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.